Gazyva

News

FDA kicks off review of Roche's Gazyva for wider lupus use

Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus.

News

Roche trial offers hope to patients with rare kidney disease

A study of Roche's Gazyva has raised the prospect of a first approved therapy for the rare kidney disorder primary membranous nephropathy.

News

Roche's Gazyva breaks new ground in lupus

Already approved for kidney damage in lupus, Roche's Gazyva could be heading for broader use in the potentially life-threatening autoimmune disorder.

News

FDA starts review of Roche's Gazyva in lupus nephritis

FDA starts a review of Roche's Gazyva as a treatment for lupus nephritis, an indication that analysts think could unlock renewed sales growth.

News

AMPLIFY results dial up Calquence's potential in CLL

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuste

FDA kicks off review of Roche's Gazyva for wider lupus use

Roche trial offers hope to patients with rare kidney disease

Roche's Gazyva breaks new ground in lupus

FDA starts review of Roche's Gazyva in lupus nephritis

AMPLIFY results dial up Calquence's potential in CLL

Parexel buys Vitrana to boost patient safety toolkit

Discover a new era of healthcare panel engagement: Grounded ...

Gazyva

Editor's Picks